Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
34346
Beskrivning
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516
Länk
https://clinicaltrials.gov/show/NCT01933516
Nyckelord
Versioner (3)
- 2019-01-16 2019-01-16 -
- 2020-04-26 2020-04-26 -
- 2020-05-01 2020-05-01 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
16 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516
Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516
- StudyEvent: Eligibility
Similar models
Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
boolean
ID.2
Item
patient with at least one measurable lesion.
boolean
ID.3
Item
patient with ecog performance status 0 or 1.
boolean
ID.4
Item
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
boolean
ID.5
Item
patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
boolean
ID.6
Item
patient who has mab therapy other than rituximab as prior line of therapy.
boolean
ID.7
Item
patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
boolean
ID.8
Item
patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean